A federal jury in Massachusetts had initially returned a $452 million verdict in December 2024, comprising $170 million in compensatory damages and $282 million in exemplary damages. A trial judge subsequently reduced that award to $59.4 million, citing double-recovery concerns arising from a permanent injunction already issued against EOFlow. The Federal Circuit's reversal of even this reduced amount represents a complete reversal of the damages phase of the case, though the status of the underlying injunction remains unclear.
Insulet and its counsel should assess whether the appellate decision affects the injunction's enforceability or scope, and whether further appeal to the Federal Circuit or Supreme Court is viable. The ruling carries significance for medtech companies pursuing trade-secret claims, potentially narrowing the circumstances under which courts will award monetary damages alongside injunctive relief in similar disputes.